today announced that its board of directors has unanimously approved a spin-off of its novel biotechnology business, Ruthigen, Inc. Oculus management is currently working with securities counsel and ...

Oculus Innovative Sciences has entered into an agreement with OroScience granting Oroscience exclusive rights to market Microcyn-based oral products in the U.S., Canada, and Europe in exchange for ...

Nov 19 (Reuters) - Oculus Innovative Sciences Inc : * Reports revenues of $4.1 million for second quarter of fiscal 2014, meeting guidance of greater than $3.6 million * Q2 revenue $4.1 million * ...

Oculus Innovative Sciences, Inc. OCLS announced today that it has entered into a definitive agreement with a single life science-focused institutional investor for the purchase of a combination of ...

Shares of Oculus Innovative Sciences (OCLS +3%) tick higher today after the company says it's been granted a CE Mark reclassification for its European formulation Dermacyn Wound Care. The newest ...

Oculus Innovative Sciences (OCLS) announces a public stock offering. It intends to use the net proceeds for the repayment of debt and to retire a portion of common stock previously issued to its ...